Loss of BMP-10 is correlated with poor survival in ovarian cancer.

Pathol Res Pract, 2019/1;215(1):121-126.

Jin Y[1], Zheng W[2], Li L[1], Huang G[3], Liu Y[4], Jiang H[1], Zhang Y[5], Tang C[6]

Affiliations

PMID: 30401582DOI: 10.1016/j.prp.2018.10.025

Impact factor: 3.309

Abstract
introduction: The expression of bone morphogenetic protein-10 (BMP-10) is downregulated in some cancer types, but its function and mechanism in ovarian cancer remains unclear.
materials and methods: BMP-10 expression was detected in ovarian cancer tissues and cell lines by using immunochemistry and western blotting. Prognostic value of BMP-10 was evaluated by Kaplan-Meier curve and Cox regression model. Knockdown or overexpression of BMP-10 was conducted by using specific siRNA or pcDNA-BMP-10 in ovarian cancer cell lines. The biological features induced by BMP-10 were observed by MTT assay, wound-healing and transwell assays.
results: BMP-10 expression in ovarian cancer tissues was significantly lower than that in ovarian tissues. Low BMP-10 expression in ovarian cancer tissues was related to advance FIGO stage, higher histologic grade, lymph node metastasis, and peritoneal fluid. Kaplan-Meier analysis revealed that low BMP-10 expression was significantly associated with poor prognosis of patients with ovarian cancer. BMP-10 overexpression or knockdown significantly inhibited or promoted proliferation, migration, and invasion of ovarian cancer cells, respectively. Moreover, administration of neutralizing antibody or human recombinant BMP-10 would reverse these effects on ovarian cancer cells.
conclusion: Low BMP-10 expression was associated with poor prognosis and progression of ovarian cancer.

Keywords: BMP-10; Metastasis; Ovarian cancer; Prognosis; Proliferation

MeSH terms
More resources
EndNote: Download